Martin D. Lehner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Martin D. Lehner has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Ashwini Tirkey
Neuroimmunology and Neurochemistry Research Group, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany
1 shared publication Beatrix C. König
Preclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Germany
1 shared publication- Bernd L. Fiebich
Neuroimmunology and Neurochemistry Research Group, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany
1 shared publication Carla Sens-Albert
Preclinical R&D, Dr. Willmar Schwabe GmbH & Co. KG, Germany
1 shared publication- Claus Normann
Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany
1 shared publication - Dominik Klett
Neuroimmunology and Neurochemistry Research Group, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany
1 shared publication
Latest Publications
- Open Access
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1673248
Proanthocyanidins from Ginkgo biloba extract EGb 761® exert antioxidative activity in vitro and antiamnesic activity in vivo
Introduction: Extracts from Ginkgo biloba leaves are widely used in the treatment of age-related cognitive decline. As regulated herbal medicinal products, these extracts are adjusted to defined contents of flavonoids and terpene lactones, which are recognized as the active constituents. Recently, proanthocyanidins (PACs) have gained increasing interest as an additional constituent group with a yet undefined role in therapeutic activity. Notably, the PAC content exhibits substantial variability across ginkgo preparations, highlighting the need for further investigation into their pharmacological relevance. Methods: In the present study, we used in vitro and in vivo assays combined with LC-(HR)-MS/MS metabolite profiling to assess the pharmacological activity, oral bioavailability, and metabolism of PACs isolated from G. biloba extract EGb 761 ® . Results: Ginkgo PACs concentration dependently reduced the basal cellular production of reactive oxygen species (ROS) in the rat neuronal cell line RN46A with higher potency than the ginkgo extract EGb 761 ® itself (IC 50 = 0.97 μg/mL vs. 3.32 μg/mL). In a T-maze model, which assessed the working memory of mice, oral pretreatment with PACs and EGb 761 ® attenuated scopolamine-induced memory impairment with similar potency and efficacy (PAC ID 50rel = 30 mg/kg, I max = 69%; EGb 761 ® ID 50rel = 39 mg/kg, I max = 68%). Gallic acid metabolites derived from PACs were detected in the plasma and urine 1 h post administration, whereas microbiota-generated metabolites of PACs were only found at later time points (6 h). The pharmacodynamic activity in the T-maze model was most prominent at 1 h post administration, indicating that the microbiota-generated metabolites did not mediate the observed pharmacological effect. Comparison of two G. biloba products compliant with regulatory specifications for terpene lactones and flavonoids but differing in the PAC content—high (5.0%) vs. low (0.6%)—revealed superior activity for the high-PAC formulation both in the in vitro ROS assay (IC 50 = 2.54 μg/mL vs. 9.01 μg/mL) and the in vivo model (63% vs. 34% reversal at 50 mg/kg). Conclusion: A PAC fraction isolated from EGb 761 ® demonstrated antioxidative activity in vitro and antiamnesic effects in vivo . These findings support the hypothesis that PACs contribute to the efficacy of EGb 761 ® .
- 27 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1673248
Open AccessProanthocyanidins from Ginkgo biloba extract EGb 761® exert antioxidative activity in vitro and antiamnesic activity in vivo
Introduction: Extracts from Ginkgo biloba leaves are widely used in the treatment of age-related cognitive decline. As regulated herbal medicinal products, these extracts are adjusted to defined contents of flavonoids and terpene lactones, which are recognized as the active constituents. Recently, proanthocyanidins (PACs) have gained increasing interest as an additional constituent group with a yet undefined role in therapeutic activity. Notably, the PAC content exhibits substantial variability across ginkgo preparations, highlighting the need for further investigation into their pharmacological relevance. Methods: In the present study, we used in vitro and in vivo assays combined with LC-(HR)-MS/MS metabolite profiling to assess the pharmacological activity, oral bioavailability, and metabolism of PACs isolated from G. biloba extract EGb 761 ® . Results: Ginkgo PACs concentration dependently reduced the basal cellular production of reactive oxygen species (ROS) in the rat neuronal cell line RN46A with higher potency than the ginkgo extract EGb 761 ® itself (IC 50 = 0.97 μg/mL vs. 3.32 μg/mL). In a T-maze model, which assessed the working memory of mice, oral pretreatment with PACs and EGb 761 ® attenuated scopolamine-induced memory impairment with similar potency and efficacy (PAC ID 50rel = 30 mg/kg, I max = 69%; EGb 761 ® ID 50rel = 39 mg/kg, I max = 68%). Gallic acid metabolites derived from PACs were detected in the plasma and urine 1 h post administration, whereas microbiota-generated metabolites of PACs were only found at later time points (6 h). The pharmacodynamic activity in the T-maze model was most prominent at 1 h post administration, indicating that the microbiota-generated metabolites did not mediate the observed pharmacological effect. Comparison of two G. biloba products compliant with regulatory specifications for terpene lactones and flavonoids but differing in the PAC content—high (5.0%) vs. low (0.6%)—revealed superior activity for the high-PAC formulation both in the in vitro ROS assay (IC 50 = 2.54 μg/mL vs. 9.01 μg/mL) and the in vivo model (63% vs. 34% reversal at 50 mg/kg). Conclusion: A PAC fraction isolated from EGb 761 ® demonstrated antioxidative activity in vitro and antiamnesic effects in vivo . These findings support the hypothesis that PACs contribute to the efficacy of EGb 761 ® .
- Open Access
- 30 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1569052
Menthacarin, a proprietary combination of peppermint and caraway oil, alters cultured human fecal microbiota composition, resulting in increased SCFA production
Background: Disruptions in the gut microbiota metabolism may contribute to the pathophysiology of gut–brain interaction disorders, and correction of intestinal dysbiosis is considered a promising therapeutic approach. Menthacarin, a proprietary fixed combination of Mentha x piperita L. and Carum carvi L. essential oils, is used clinically for the treatment of functional dyspepsia and irritable bowel syndrome. Rodent model data indicate that treatment effects of Menthacarin on visceral hypersensitivity could be mediated via the normalization of gut dysbiosis. However, the impact of Menthacarin on human bacterial gut microbiota has not yet been studied.Aim: The aim of the present study was to assess whether Menthacarin affects the composition and metabolic activity of human fecal microbiota.Methods: Fecal slurry samples from 10 healthy volunteers were cultivated for 36 h under anoxic conditions with and without Menthacarin. Relative bacterial abundance at the phylum and genus levels was evaluated using 16S rRNA metagenomic analysis. Short-chain fatty acids (SCFAs) in the supernatants were measured using the LC-MS technology.Results: Menthacarin induced robust changes in microbial composition at both the phylum and genus levels among the 10 donor microbiomes. The relative abundance of Firmicutes (+13.6 ± 8.6%) and Actinobacteria (+54.9 ± 47.6%) significantly increased, whereas that of Bacteroidetes (−27.7% ± 21.9%) and Proteobacteria (−25.7% ± 12.3%) significantly decreased in the presence of Menthacarin. At the genus level, the most notable changes were significant increases in Bifidobacterium (+105.1 ± 78.4%) and several SCFA-producing genera accompanied by a significant decrease in genera containing members involved in pro-inflammatory processes. In addition, Menthacarin significantly increased the levels of several SCFAs, namely, propionate, butyrate, isobutyrate, valerate, and isovalerate.Conclusion: Menthacarin alters the microbiota composition and enhances SCFA production in human microbiota samples under in vitro conditions. These effects may contribute to the clinical benefits observed with Menthacarin treatment.
- 30 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1569052
Open AccessMenthacarin, a proprietary combination of peppermint and caraway oil, alters cultured human fecal microbiota composition, resulting in increased SCFA production
Background: Disruptions in the gut microbiota metabolism may contribute to the pathophysiology of gut–brain interaction disorders, and correction of intestinal dysbiosis is considered a promising therapeutic approach. Menthacarin, a proprietary fixed combination of Mentha x piperita L. and Carum carvi L. essential oils, is used clinically for the treatment of functional dyspepsia and irritable bowel syndrome. Rodent model data indicate that treatment effects of Menthacarin on visceral hypersensitivity could be mediated via the normalization of gut dysbiosis. However, the impact of Menthacarin on human bacterial gut microbiota has not yet been studied.Aim: The aim of the present study was to assess whether Menthacarin affects the composition and metabolic activity of human fecal microbiota.Methods: Fecal slurry samples from 10 healthy volunteers were cultivated for 36 h under anoxic conditions with and without Menthacarin. Relative bacterial abundance at the phylum and genus levels was evaluated using 16S rRNA metagenomic analysis. Short-chain fatty acids (SCFAs) in the supernatants were measured using the LC-MS technology.Results: Menthacarin induced robust changes in microbial composition at both the phylum and genus levels among the 10 donor microbiomes. The relative abundance of Firmicutes (+13.6 ± 8.6%) and Actinobacteria (+54.9 ± 47.6%) significantly increased, whereas that of Bacteroidetes (−27.7% ± 21.9%) and Proteobacteria (−25.7% ± 12.3%) significantly decreased in the presence of Menthacarin. At the genus level, the most notable changes were significant increases in Bifidobacterium (+105.1 ± 78.4%) and several SCFA-producing genera accompanied by a significant decrease in genera containing members involved in pro-inflammatory processes. In addition, Menthacarin significantly increased the levels of several SCFAs, namely, propionate, butyrate, isobutyrate, valerate, and isovalerate.Conclusion: Menthacarin alters the microbiota composition and enhances SCFA production in human microbiota samples under in vitro conditions. These effects may contribute to the clinical benefits observed with Menthacarin treatment.
- Open Access
- 15 December 2024
- Published by Elsevier in Phytomedicine
- Vol. 136, 156327
Ginkgo biloba extract EGb 761® ameliorates cognitive impairment and alleviates TNFα response in 5xFAD Alzheimer‘s disease model mice
- 15 December 2024
- Published by Elsevier in Phytomedicine
- Vol. 136, 156327
Open AccessGinkgo biloba extract EGb 761® ameliorates cognitive impairment and alleviates TNFα response in 5xFAD Alzheimer‘s disease model mice
- Open Access
- 27 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
A combination of carbonates and Opuntia ficus-indica extract protects esophageal cells against simulated acidic and non-acidic reflux in vitro
Buffering of stomach acid by antacids is a well-established symptomatic therapy for heartburn. In addition, preparations from prickly pear (Opuntia ficus-indica) have been shown to reduce tissue damage in experimental gastritis models and to attenuate gastrointestinal discomfort in patients. Both active principles have been included in a fixed-combination product for symptomatic treatment of heartburn containing carbonate antacids (CaCO3 and MgCO3) and an extract from Opuntia ficus-indica cladodes. The aim of the study was to characterize the acid neutralization and esophageal cell protective activities of the product and its individual active ingredients in a set of in vitro assays. Acid neutralization was assessed in a simulated stomach model. Protective activity of individual constituents and in combination was analyzed in an esophageal cell line (COLO-680 N) exposed to low pH and deoxycholic acid to simulate acidic and non-acidic reflux challenge. The combination product protected cells against low pH mediated cytotoxicity via acid neutralization by carbonates. Opuntia extract itself and the combination product attenuated bile acid-induced cell irritation as measured by reduced release of proinflammatory interleukin-6 and -8. In conclusion, addition of Opuntia extract to a mineral antacid provides dual protection against acidic and non-acidic simulated reflux challenge.
- 27 September 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-11
Open AccessA combination of carbonates and Opuntia ficus-indica extract protects esophageal cells against simulated acidic and non-acidic reflux in vitro
Buffering of stomach acid by antacids is a well-established symptomatic therapy for heartburn. In addition, preparations from prickly pear (Opuntia ficus-indica) have been shown to reduce tissue damage in experimental gastritis models and to attenuate gastrointestinal discomfort in patients. Both active principles have been included in a fixed-combination product for symptomatic treatment of heartburn containing carbonate antacids (CaCO3 and MgCO3) and an extract from Opuntia ficus-indica cladodes. The aim of the study was to characterize the acid neutralization and esophageal cell protective activities of the product and its individual active ingredients in a set of in vitro assays. Acid neutralization was assessed in a simulated stomach model. Protective activity of individual constituents and in combination was analyzed in an esophageal cell line (COLO-680 N) exposed to low pH and deoxycholic acid to simulate acidic and non-acidic reflux challenge. The combination product protected cells against low pH mediated cytotoxicity via acid neutralization by carbonates. Opuntia extract itself and the combination product attenuated bile acid-induced cell irritation as measured by reduced release of proinflammatory interleukin-6 and -8. In conclusion, addition of Opuntia extract to a mineral antacid provides dual protection against acidic and non-acidic simulated reflux challenge.
- Open Access
- 25 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8108
Anti-Neuroinflammatory Effects of Ginkgo biloba Extract EGb 761 in LPS-Activated BV2 Microglial Cells
Inflammatory processes in the brain can exert important neuroprotective functions. However, in neurological and psychiatric disorders, it is often detrimental due to chronic microglial over-activation and the dysregulation of cytokines and chemokines. Growing evidence indicates the emerging yet prominent pathophysiological role of neuroinflammation in the development and progression of these disorders. Despite recent advances, there is still a pressing need for effective therapies, and targeting neuroinflammation is a promising approach. Therefore, in this study, we investigated the anti-neuroinflammatory potential of a marketed and quantified proprietary herbal extract of Ginkgo biloba leaves called EGb 761 (10–500 µg/mL) in BV2 microglial cells stimulated by LPS (10 ng/mL). Our results demonstrate significant inhibition of LPS-induced expression and release of cytokines tumor necrosis factor-α (TNF-α) and Interleukin 6 (IL-6) and chemokines C-X-C motif chemokine ligand 2 (CXCL2), CXCL10, c-c motif chemokine ligand 2 (CCL2) and CCL3 in BV2 microglial cells. The observed effects are possibly mediated by the mitogen-activated protein kinases (MAPK), p38 MAPK and ERK1/2, as well as the protein kinase C (PKC) and the nuclear factor (NF)-κB signaling cascades. The findings of this in vitro study highlight the anti-inflammatory properties of EGb 761 and its therapeutic potential, making it an emerging candidate for the treatment of neuroinflammatory diseases and warranting further research in pre-clinical and clinical settings.
- 25 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8108
Open AccessAnti-Neuroinflammatory Effects of Ginkgo biloba Extract EGb 761 in LPS-Activated BV2 Microglial Cells
Inflammatory processes in the brain can exert important neuroprotective functions. However, in neurological and psychiatric disorders, it is often detrimental due to chronic microglial over-activation and the dysregulation of cytokines and chemokines. Growing evidence indicates the emerging yet prominent pathophysiological role of neuroinflammation in the development and progression of these disorders. Despite recent advances, there is still a pressing need for effective therapies, and targeting neuroinflammation is a promising approach. Therefore, in this study, we investigated the anti-neuroinflammatory potential of a marketed and quantified proprietary herbal extract of Ginkgo biloba leaves called EGb 761 (10–500 µg/mL) in BV2 microglial cells stimulated by LPS (10 ng/mL). Our results demonstrate significant inhibition of LPS-induced expression and release of cytokines tumor necrosis factor-α (TNF-α) and Interleukin 6 (IL-6) and chemokines C-X-C motif chemokine ligand 2 (CXCL2), CXCL10, c-c motif chemokine ligand 2 (CCL2) and CCL3 in BV2 microglial cells. The observed effects are possibly mediated by the mitogen-activated protein kinases (MAPK), p38 MAPK and ERK1/2, as well as the protein kinase C (PKC) and the nuclear factor (NF)-κB signaling cascades. The findings of this in vitro study highlight the anti-inflammatory properties of EGb 761 and its therapeutic potential, making it an emerging candidate for the treatment of neuroinflammatory diseases and warranting further research in pre-clinical and clinical settings.
- Open Access
- 7 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 11230
EPs® 7630 Stimulates Tissue Repair Mechanisms and Modifies Tight Junction Protein Expression in Human Airway Epithelial Cells
Airway epithelium repair after infection consists of wound repair, re-synthesis of the extracellular matrix (ECM), and tight junction proteins. In humans, EPs® 7630 obtained from Pelargonium sidoides roots reduces the severity and duration of acute respiratory tract infections. The effect of EPs® 7630 on tissue repair of rhinovirus-16 (RV-16) infected and control human airway epithelial cells was assessed for: (i) epithelial cell proliferation by manual cell counts, (ii) epithelial wound repair by “scratch assay”, (iii) ECM composition by Western-blotting and cell-based ELISA, and (iv) epithelial tight junction proteins by Western-blotting. EPs® 7630 stimulated cell proliferation through cAMP, CREB, and p38 MAPK. EPs® 7630 significantly improved wound repair. Pro-inflammatory collagen type-I expression was reduced by EPs® 7630, while fibronectin was increased. Virus-binding tight junction proteins desmoglein2, desmocollin2, ZO-1, claudin1, and claudin4 were downregulated by EPs® 7630. The RV16-induced shift of the ECM towards the pro-inflammatory type was prevented by EPs® 7630. Most of the effects of EPs® 7630 on tissue repair and regeneration were sensitive to inhibition of cAMP-induced signaling. The data suggest that EPs® 7630-dependent modification of epithelial cell metabolism and function might underlie the faster recovery time from viral infections, as reported by others in clinical studies.
- 7 July 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (13) , 11230
Open AccessEPs® 7630 Stimulates Tissue Repair Mechanisms and Modifies Tight Junction Protein Expression in Human Airway Epithelial Cells
Airway epithelium repair after infection consists of wound repair, re-synthesis of the extracellular matrix (ECM), and tight junction proteins. In humans, EPs® 7630 obtained from Pelargonium sidoides roots reduces the severity and duration of acute respiratory tract infections. The effect of EPs® 7630 on tissue repair of rhinovirus-16 (RV-16) infected and control human airway epithelial cells was assessed for: (i) epithelial cell proliferation by manual cell counts, (ii) epithelial wound repair by “scratch assay”, (iii) ECM composition by Western-blotting and cell-based ELISA, and (iv) epithelial tight junction proteins by Western-blotting. EPs® 7630 stimulated cell proliferation through cAMP, CREB, and p38 MAPK. EPs® 7630 significantly improved wound repair. Pro-inflammatory collagen type-I expression was reduced by EPs® 7630, while fibronectin was increased. Virus-binding tight junction proteins desmoglein2, desmocollin2, ZO-1, claudin1, and claudin4 were downregulated by EPs® 7630. The RV16-induced shift of the ECM towards the pro-inflammatory type was prevented by EPs® 7630. Most of the effects of EPs® 7630 on tissue repair and regeneration were sensitive to inhibition of cAMP-induced signaling. The data suggest that EPs® 7630-dependent modification of epithelial cell metabolism and function might underlie the faster recovery time from viral infections, as reported by others in clinical studies.
- Open Access
- 1 October 2021
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 116, 103669
Pharmacologic treatments in preclinical tinnitus models with special focus on Ginkgo biloba leaf extract EGb 761®
- 1 October 2021
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 116, 103669
Open AccessPharmacologic treatments in preclinical tinnitus models with special focus on Ginkgo biloba leaf extract EGb 761®